Genetic variations make Lyme harder to treat

This family’s repeated strep throat infections frustrated their doctors

By  Sandra G. Boodman

May 23, 2020

When Dan Levitis, his wife, Iris, and their three young children trooped into a Madison, Wis., urgent care clinic around 8 a.m. on New Year’s Day 2018, the staff didn’t seem surprised to see them. The family had sought treatment several times in the previous two months for recurrent strep throat infections.

They had taken multiple rounds of drugs, professionally deep cleaned their home and replaced contaminated toothbrushes, but none of it worked for long. Inevitably, the infection came roaring back.  (See link for article)



A very intriguing case.  Important excerpts:

Levitis called his mother, a retired pediatrician who had practiced in suburban Maryland, for advice. She told him about a family she had seen who kept getting strep until they got rid of their pet cat.

While a report from the American Veterinary Medical Association states that doctors sometimes blame pets for recurrent strep throat infections, “evidence doesn’t support this.”

To the surprise of the vet school faculty, group A strep was found in the cat’s throat; it appeared to match the strain of strep collected during Levitis’s most recent throat culture.

This case shows that clinical doctors often know things medical associations don’t!

The family went on vacation, (all treated with antibiotics) and their house was professionally cleaned for the second time, while the asymptomatic cat was also given antibiotics and disinfectant spray for his fur, which finally put a stop to the endless strep infections.

Due to the denial of most of the doctors and their corresponding unwillingness to swab the cat’s throat, this case almost went unsolved.  Food for thought, and another reminder to be willing to fight for answers.

For more:

These articles are just the tip of the ice-berg.  I hope this makes it crystal clear that Bartonella is NOT RARE!  By Children’s Health Defense Team

Excerpts from article:

  • On Monday, Moderna announced that its mRNA-1273 COVID vaccine candidate was 94.5% effective, based on interim Phase 3 trial data.

  • Last week Pfizer announced that analysis of preliminary Phase 3 trial data indicated its BNT162b2 COVID vaccine, developed in partnership with Germany’s BioNTech, was “more than 90% effective.”

Both announcements came in the form of press releases — with neither company providing the actual data behind their claims.

In short, neither company can state if and how long the vaccine will provide protection, yet they are seeking EUA status from the FDA, which BTW will allow them to skip standard safety and compliance standards.  Isn’t that nice?

The press release caused stock to rise yet according to STAT:

“Every Tuesday Moderna’s top doctor gets about $1million richer” by selling his existing stock like clockwork through pre-scheduled trades, “earning him more than $50 million since the dawn of the pandemic.

Pfizer CEO Albert Bourla also sold $5.6 million of Pfizer stock on the same day the vaccine maker made its “90% effective” announcement.

The article then points out that a high amount of ADRs are expected, which I posted about here:

The vaccine by Moderna:  By  Rob Verkerk PhD

In this article, the author points out that Pfizer’s claim that its vaccine is 90% effective is unsubstantiated by Peer-reviewed journals and the WHO. Since it is excluded from Operation Warp Speed it didn’t need to share its data to a monitoring committee.

Further, press released statements don’t prove anything.

Evidently, Pfizer’s Phase 3 trial was reported on my an “external, anonymous independent Data Monitoring Committee (DMC)” which according to the Kaiser Family Foundation is anything but independent.  Source: article 

This report on the interim study results simply can not be found.

The author points out that the press release points to unknowns such as the possibility that some of the confirmed cases could be other coronaviruses that have triggered immunogenicity which means results are either false positives OR COVID-19 viral fragments, as well as the fact these dead viral fragments triggering immunogenic reactions could not have caused infection anyway.

Peter Doshi, an associated editor of the BMJ and also associate professor of pharmaceutical health services at the University of Maryland School of Pharmacy, “The lack of data is very concerning … All we have right now is a headline by Pfizer.”

And then there’s that needling issue about risk of vaccine harm such as triggering autoimmune conditions which can not be detected in the study’s few months of reporting, as well as the fact the vaccine might fail to be effective just a few months after the second dose.

Verkerk goes onto question governments’ risk-cost-benefit analysis justifying the rollout of these vaccines.  There are effective treatments, and herd immunity is very real and attainable:

For more on this:  


  1. Firstly, it was wrong to claim that this virus was novel.
  2. Secondly, It was even more wrong to claim that the population would not already have some immunity against this virus.
  3. Thirdly, it was the crowning of stupidity to claim that someone could have Covid-19 without any symptoms at all or even to pass the disease along without showing any symptoms whatsoever.  News videos here

Promising treatment brings new hope for patients with chronic Lyme disease

W5 Producer
Published Friday, November 20, 2020 
W5’s Molly Thomas speaks to a Canadian Lyme disease patient who had to struggle for years just to get a diagnosis.
There are more ticks in Canada than ever before, but is the country’s health care system prepared to deal with more Lyme disease cases?
Nikki Kent had to go through a battery of tests and years of uncertainty before she was finally diagnosed with Lyme disease.
Informative Canadian news series on Lyme disease.
The series looks at a number of Canadian Lyme patients that have had trouble obtaining diagnosis and treatment in Canada, necessitating they travel thousands of miles to the United States.
The series points out the:
There is a myth still being perpetrated in the medical community on the effectiveness of 1 or 2 doses of doxycycline:

Daniel J. Cameron, MD MPH, states there has only been one study (Nadelman et al) on the effectiveness of 1 pill of doxycycline and only found a reduction in the number of erythema migraines (EM) rashes compared to the placebo group.  According to him, the IDSA 1 pill of doxy approach started in 2006 despite the fact that three previous prophylactic antibiotic trials for a tick bite had failed.

Only one study in 2001 tested this hypothesis at one hospital in New York.

For the study, the bullseye rash was the diagnostic criteria to determine if doxy prevented LD. The study actually showed that people bitten by nymphs were more likely to develop a bullseye rash and therefore diagnosed with LD in comparison with those bitten by an adult tick. None of those bitten by adult ticks developed a bullseye rash.

The Bullseye is a poor indicator of LD.

Only 50% with LD got any kind of rash and only 9% developed a bullseye.

Two pills used at the time of tick bite by a nymph prevented people from getting the bullseye – so they were not diagnosed as having LDand were excluded from the study.

So, will 2 pills of doxy prevent Lyme?


So much for evidence based medicine.
The article in the top link then goes onto discuss Dr. Tim Cook who has had success using disulfiram/Antabuse.  He quotes:
“OK, now this is exciting,” he said. “Disulfram (DSF) is a breakthrough because it is one of only two or three medications that are known to specifically target the slow-growth phase of Lyme that regular antibiotics do not eradicate.”
“What has surprised me is how patients improve with very little of it. Prior to DSF, the conventional combinations of antibiotics would make most patients feel quite a bit better, but they would often say that their ‘brain fog’ and fatigue never quite went away. These two symptoms are often completely and rapidly resolved with DSF,” Dr. Cook said.

http://” data-wplink-url-error=”true”>a; gyroscope; picture-in-picture” allowfullscreen></iframe>  Approx. 12 Min

5th Annual LymeMIND Virtual Conference 2020 Saturday, October 10th

Hosted by “Icahn School of Medicine at Mount Sinai proudly supported by the Steven & Alexandra Cohen Foundation: Cohen Lyme & Tickborne Disease Initiative”
Looking towards the future
  • Bennett Nemser, MPH, MBA, Senior Program Officer, Steven & Alexandra Cohen Foundation
  • Brian A. Fallon, MD MPH, Director, Lyme & Tickborne Diseases Research Center, Columbia University Irving Medical Center
  • John Aucott, MD, Associate Professor Director, Lyme Disease Research Center Johns Hopkins University School of Medicine Looking towards the Future
Discussion of innovative new projects that will help translate scientific breakthroughs into improved patient care over the next four (4) years.